ProCE Banner Activity

ADCs with Alternative HER2 Targeting Mechanisms and Beyond HER2-Positive Disease: Expanding Potential Benefit to Other Breast Cancer Subsets

Slideset Download

Download this slideset to review the latest data on new directions using antibody drug conjugates in HER2-positive breast cancer and beyond.

Released: October 30, 2020

Share

Faculty

Javier Cortes

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain